HTX-019 is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant, a substance P/NK1 receptor antagonist, as a 30-second IV injection.
Intraoperative administration of dexamethasone linked to reduced 90-day mortality after surgery to remove solid tumors
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Barhemsys is a selective dopamine-2 and dopamine-3 receptor antagonist.
Akynzeo is a combination of palonosetron, a 5-HT3 receptor antagonist, and fosnetupitant, a substance P/NK1 receptor antagonist.
The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
Adding furosemide with or without sodium chloride to fluid restriction is not more effective than fluid restriction alone at correcting hyponatremia in patients with the syndrome of inappropriate antidiuresis, a study found.
The FDA has approved Barhemsys (amisulpride; Acacia Pharma) for the prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class and for the treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
Cinvanti injectable emulsion can be administered as a 2-minute intravenous injection or 30-minute intravenous infusion.
